Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,22552003,extraction recovery,The extraction recovery of ABA was between 89.1% and 100.7%.,"Determination of aniracetam's main metabolite, N-anisoyl-GABA, in human plasma by LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22552003/),%,89.1,11138,DB00722,Lisinopril
,22552003,extraction recovery,The extraction recovery of ABA was between 89.1% and 100.7%.,"Determination of aniracetam's main metabolite, N-anisoyl-GABA, in human plasma by LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22552003/),%,100.7,11139,DB00722,Lisinopril
,7995322,maximal serum concentration (Cmax),After 15 days of lisinopril treatment the mean maximal serum concentration (Cmax) in patients was lower than in volunteers (30.7 vs 40.7 ng.,Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995322/),ng,30.7,23007,DB00722,Lisinopril
,7995322,maximal serum concentration (Cmax),After 15 days of lisinopril treatment the mean maximal serum concentration (Cmax) in patients was lower than in volunteers (30.7 vs 40.7 ng.,Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995322/),ng,40.7,23008,DB00722,Lisinopril
,7995322,area under the concentration-time curve (AUC0-24 h),"ml-1, while the mean area under the concentration-time curve (AUC0-24 h) was higher (525 vs 473 ng.h-1.ml-1).",Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995322/),[ng] / [h·ml],525,23009,DB00722,Lisinopril
,7995322,area under the concentration-time curve (AUC0-24 h),"ml-1, while the mean area under the concentration-time curve (AUC0-24 h) was higher (525 vs 473 ng.h-1.ml-1).",Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995322/),[ng] / [h·ml],473,23010,DB00722,Lisinopril
,2527539,Di,6. Dialysis clearance was approximately 2 l h-1 for cilazapril and for cilazaprilat.,Pharmacokinetics of cilazapril in patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2527539/),[l] / [h],2,28907,DB00722,Lisinopril
,2550637,AUC0-48 h,Co-administration of hydralazine significantly increased the area under the plasma concentration time curve (AUC) of lisinopril (AUC0-48 h 766.8 +/- 66.3 ng.h/ml (lisinopril) vs 1022.3 +/- 115.3 ng.h/ml (lisinopril + hydralazine)).,"Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550637/),[h·ng] / [ml],766.8,48253,DB00722,Lisinopril
,2550637,AUC0-48 h,Co-administration of hydralazine significantly increased the area under the plasma concentration time curve (AUC) of lisinopril (AUC0-48 h 766.8 +/- 66.3 ng.h/ml (lisinopril) vs 1022.3 +/- 115.3 ng.h/ml (lisinopril + hydralazine)).,"Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550637/),[h·ng] / [ml],1022.3,48254,DB00722,Lisinopril
,2550637,AUC,This did not occur with enalaprilat (AUC 710.1 +/- 51.2 ng.h/ml (enalapril) vs 681.9 +/- 44.9 ng.h/ml (enalapril + hydralazine); mean +/- SEM).,"Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550637/),[h·ng] / [ml],710.1,48255,DB00722,Lisinopril
,2550637,AUC,This did not occur with enalaprilat (AUC 710.1 +/- 51.2 ng.h/ml (enalapril) vs 681.9 +/- 44.9 ng.h/ml (enalapril + hydralazine); mean +/- SEM).,"Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550637/),[h·ng] / [ml],681.9,48256,DB00722,Lisinopril
,17216247,C(max),"C(max) of lisinopril, which occurred 5-6 h postdose, varied from 22 ng/ml in Groups I and II to 44 ng/ml in Groups III and IV; AUC(0-24 h) ranged from 301-311 ng.h/ml in Groups I and II to 550-570 ng.h/ml in Groups III and IV.",A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216247/),[ng] / [ml],22,50074,DB00722,Lisinopril
,17216247,C(max),"C(max) of lisinopril, which occurred 5-6 h postdose, varied from 22 ng/ml in Groups I and II to 44 ng/ml in Groups III and IV; AUC(0-24 h) ranged from 301-311 ng.h/ml in Groups I and II to 550-570 ng.h/ml in Groups III and IV.",A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216247/),[ng] / [ml],44,50075,DB00722,Lisinopril
,17216247,AUC(0-24 h),"C(max) of lisinopril, which occurred 5-6 h postdose, varied from 22 ng/ml in Groups I and II to 44 ng/ml in Groups III and IV; AUC(0-24 h) ranged from 301-311 ng.h/ml in Groups I and II to 550-570 ng.h/ml in Groups III and IV.",A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216247/),[h·ng] / [ml],301-311,50076,DB00722,Lisinopril
,17216247,AUC(0-24 h),"C(max) of lisinopril, which occurred 5-6 h postdose, varied from 22 ng/ml in Groups I and II to 44 ng/ml in Groups III and IV; AUC(0-24 h) ranged from 301-311 ng.h/ml in Groups I and II to 550-570 ng.h/ml in Groups III and IV.",A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216247/),[h·ng] / [ml],550-570,50077,DB00722,Lisinopril
,2550636,maximum serum concentration (Cmax),"The maximum serum concentration (Cmax) of lisinopril and time to reach maximum concentration (Tmax) were 64 +/- 16 ng/ml and 7.5 +/- 1.5 h, respectively.","Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),[ng] / [ml],64,52064,DB00722,Lisinopril
,2550636,time to reach maximum concentration (Tmax),"The maximum serum concentration (Cmax) of lisinopril and time to reach maximum concentration (Tmax) were 64 +/- 16 ng/ml and 7.5 +/- 1.5 h, respectively.","Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),h,7.5,52065,DB00722,Lisinopril
,2550636,area under the serum curve (AUC),The area under the serum curve (AUC) was 916 +/- 239 h.,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),h,916,52066,DB00722,Lisinopril
,2550636,Cmax,The Cmax of enalaprilat (89 +/- 34 ng/ml) was greater than that of lisinopril whilst Tmax was shorter (4.3 +/- 1.7 h) and AUC smaller (718 +/- 17 h.ng/ml) (P less than 0.01).,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),[ng] / [ml],89,52067,DB00722,Lisinopril
,2550636,Tmax,The Cmax of enalaprilat (89 +/- 34 ng/ml) was greater than that of lisinopril whilst Tmax was shorter (4.3 +/- 1.7 h) and AUC smaller (718 +/- 17 h.ng/ml) (P less than 0.01).,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),h,4.3,52068,DB00722,Lisinopril
,2550636,AUC,The Cmax of enalaprilat (89 +/- 34 ng/ml) was greater than that of lisinopril whilst Tmax was shorter (4.3 +/- 1.7 h) and AUC smaller (718 +/- 17 h.ng/ml) (P less than 0.01).,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),[h·ng] / [ml],718,52069,DB00722,Lisinopril
,2550636,Renal clearance of drug,Renal clearance of drug 48 h post-dosing showed that enalaprilat (164 +/- 38 ml/min) was cleared from plasma significantly more rapidly than lisinopril (82 +/- 16 ml/min) (P less than 0.001).,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),[ml] / [min],164,52070,DB00722,Lisinopril
,2550636,Renal clearance of drug,Renal clearance of drug 48 h post-dosing showed that enalaprilat (164 +/- 38 ml/min) was cleared from plasma significantly more rapidly than lisinopril (82 +/- 16 ml/min) (P less than 0.001).,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),[ml] / [min],82,52071,DB00722,Lisinopril
lower,7512472,trough: peak ratios,Other ACE inhibitors had trough: peak ratios lower than 50%.,Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7512472/),,50,61290,DB00722,Lisinopril
,6100875,accumulation half-life,Comparison between the observed and predicted steady-state urinary recoveries of enalaprilat yields an effective accumulation half-life of approximately 11 h.,Kinetic and metabolic aspects of enalapril action. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6100875/),h,11,63271,DB00722,Lisinopril
,2849471,IC50,"Calculated IC50 was 47 ng lisinopril ml-1. from pooled data, with individual patients IC50 ranging from 20 to 70 ng lisinopril ml-1.",Lisinopril pharmacokinetics in chronic renal failure. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849471/),[lisinopril·ng] / [ml],47,69673,DB00722,Lisinopril
,2849471,IC50,"Calculated IC50 was 47 ng lisinopril ml-1. from pooled data, with individual patients IC50 ranging from 20 to 70 ng lisinopril ml-1.",Lisinopril pharmacokinetics in chronic renal failure. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849471/),[lisinopril·ng] / [ml],20 to 70,69674,DB00722,Lisinopril
,16484515,apparent volume of distribution,The mean apparent volume of distribution after administration of a single subcutaneous dose is 28.3 L.,Exenatide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),l,28.3,93631,DB00722,Lisinopril
,16484515,terminal half-life,The terminal half-life of the drug is 2.4 hours.,Exenatide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),h,2.4,93632,DB00722,Lisinopril
,16484515,bioavailability,"Based on animal studies, the bioavailability of exenatide after subcutaneous injection has been estimated to be between 65% and 75%.",Exenatide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),%,65,93633,DB00722,Lisinopril
,16484515,bioavailability,"Based on animal studies, the bioavailability of exenatide after subcutaneous injection has been estimated to be between 65% and 75%.",Exenatide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),%,75,93634,DB00722,Lisinopril
,3014110,area under the serum concentration-time curve (AUC0-120h,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),[h·ng] / [ml],1231,97037,DB00722,Lisinopril
,3014110,area under the serum concentration-time curve (AUC0-120h,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),[h·ng] / [ml],1029,97038,DB00722,Lisinopril
,3014110,peak lisinopril serum concentration,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),[ng] / [ml],86,97039,DB00722,Lisinopril
,3014110,peak lisinopril serum concentration,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),[ng] / [ml],69,97040,DB00722,Lisinopril
,3014110,time to peak lisinopril serum concentration,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),h,6.2,97041,DB00722,Lisinopril
,3014110,time to peak lisinopril serum concentration,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),h,6.8,97042,DB00722,Lisinopril
,3014110,urinary excretion,Five-day urinary excretion of lisinopril was not altered by food (5.3 +/- 3.0 versus 5.1 +/- 2.0 mg).,"Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),mg,5.3,97043,DB00722,Lisinopril
,3014110,urinary excretion,Five-day urinary excretion of lisinopril was not altered by food (5.3 +/- 3.0 versus 5.1 +/- 2.0 mg).,"Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),mg,5.1,97044,DB00722,Lisinopril
,3014110,bioavailability,"Based on the urinary data, the mean +/- SD bioavailability of lisinopril was not different following fasting or fed regimens (27 +/- 15 versus 26 +/- 10%).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),%,27,97045,DB00722,Lisinopril
,3014110,bioavailability,"Based on the urinary data, the mean +/- SD bioavailability of lisinopril was not different following fasting or fed regimens (27 +/- 15 versus 26 +/- 10%).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),%,26,97046,DB00722,Lisinopril
,2853960,plasma clearance,4. Haemodialysis plasma clearance was similar for both drugs with mean values of the order of 40 ml min-1.,"Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2853960/),[ml] / [min],40,100439,DB00722,Lisinopril
,33986677,bioavailability,"Inter-compartmental clearance (from plasma to periphery) for the irradiated rats was lower than for the nonirradiated rats (ratio 0.615, p = 0.003), while the bioavailability of the drug was 33% higher (ratio = 1.326, p < 0.001).","Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33986677/),%,33,105418,DB00722,Lisinopril
,8877596,CE50,"Emax was fixed at -100%, and we obtained (mean +/- SD) CE50 = 1.4 +/- 0.6 ng/ml and gamma = 0.6 +/- 0.1.",Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877596/),[ng] / [ml],1.4,105488,DB00722,Lisinopril
,8877596,gamma,"Emax was fixed at -100%, and we obtained (mean +/- SD) CE50 = 1.4 +/- 0.6 ng/ml and gamma = 0.6 +/- 0.1.",Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877596/),,0.6,105489,DB00722,Lisinopril
,8877596,Emax,"We obtained Emax = 45 +/- 20 ml/min, CE50 = 24.0 +/- 12.4 ng/ml, and gamma = 3.2 +/- 1.3 for BAF, and Emax = -45 +/- 15%, CE50 = 22.0 +/- 10.2 ng/ml, and gamma = 3.1 +/- 1.1 for BVR.",Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877596/),[ml] / [min],45,105490,DB00722,Lisinopril
,8877596,CE50,"We obtained Emax = 45 +/- 20 ml/min, CE50 = 24.0 +/- 12.4 ng/ml, and gamma = 3.2 +/- 1.3 for BAF, and Emax = -45 +/- 15%, CE50 = 22.0 +/- 10.2 ng/ml, and gamma = 3.1 +/- 1.1 for BVR.",Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877596/),[ng] / [ml],24.0,105491,DB00722,Lisinopril
,8877596,gamma,"We obtained Emax = 45 +/- 20 ml/min, CE50 = 24.0 +/- 12.4 ng/ml, and gamma = 3.2 +/- 1.3 for BAF, and Emax = -45 +/- 15%, CE50 = 22.0 +/- 10.2 ng/ml, and gamma = 3.1 +/- 1.1 for BVR.",Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877596/),,3.2,105492,DB00722,Lisinopril
,8877596,Emax,"We obtained Emax = 45 +/- 20 ml/min, CE50 = 24.0 +/- 12.4 ng/ml, and gamma = 3.2 +/- 1.3 for BAF, and Emax = -45 +/- 15%, CE50 = 22.0 +/- 10.2 ng/ml, and gamma = 3.1 +/- 1.1 for BVR.",Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877596/),%,-45,105493,DB00722,Lisinopril
,8877596,CE50,"We obtained Emax = 45 +/- 20 ml/min, CE50 = 24.0 +/- 12.4 ng/ml, and gamma = 3.2 +/- 1.3 for BAF, and Emax = -45 +/- 15%, CE50 = 22.0 +/- 10.2 ng/ml, and gamma = 3.1 +/- 1.1 for BVR.",Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877596/),[ng] / [ml],22.0,105494,DB00722,Lisinopril
,8877596,gamma,"We obtained Emax = 45 +/- 20 ml/min, CE50 = 24.0 +/- 12.4 ng/ml, and gamma = 3.2 +/- 1.3 for BAF, and Emax = -45 +/- 15%, CE50 = 22.0 +/- 10.2 ng/ml, and gamma = 3.1 +/- 1.1 for BVR.",Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877596/),,3.1,105495,DB00722,Lisinopril
,22007522,fluctuation index (FI),"Administered with the test medication, lisinopril has an fluctuation index (FI) value of 2.29 and reaches a relative steady concentration.",Pharmacokinetics of the combined preparation of lisinopril and hydrochlorothiazide on Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007522/),,2.29,108150,DB00722,Lisinopril
,22007522,FI,But hydrochlorothiazide has an FI value of 4.09 with relatively large fluctuating concentrations.,Pharmacokinetics of the combined preparation of lisinopril and hydrochlorothiazide on Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007522/),,4.09,108151,DB00722,Lisinopril
,9740616,half-life (t1/2),"In vehicle-treated SD, SHR and TG+ the half-life (t1/2) of Ang-(1-7) averaged 10+/-1, 10+/-1, and 9+/-1 seconds, respectively.",Converting enzyme determines plasma clearance of angiotensin-(1-7). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9740616/),seconds,10,120673,DB00722,Lisinopril
,9740616,half-life (t1/2),"In vehicle-treated SD, SHR and TG+ the half-life (t1/2) of Ang-(1-7) averaged 10+/-1, 10+/-1, and 9+/-1 seconds, respectively.",Converting enzyme determines plasma clearance of angiotensin-(1-7). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9740616/),seconds,9,120674,DB00722,Lisinopril
,2844083,oral bioavailability,"The angiotensin-converting enzyme inhibitor, lisinopril, has an oral bioavailability of 25 percent +/- 4 percent, which is unaffected by food.",Pharmacokinetics of lisinopril. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2844083/),%,25,139309,DB00722,Lisinopril
,2844083,accumulation half-life,The accumulation half-life averages 12.6 hours despite a terminal serum half-life of approximately 40 hours.,Pharmacokinetics of lisinopril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2844083/),h,12.6,139310,DB00722,Lisinopril
,2844083,terminal serum half-life,The accumulation half-life averages 12.6 hours despite a terminal serum half-life of approximately 40 hours.,Pharmacokinetics of lisinopril. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2844083/),h,40,139311,DB00722,Lisinopril
,24561703,IC50,The IC50 value of LisW-S was 38.5 nM in rat plasma using the fluorogenic substrate Abz-FRKP(Dnp)P-OH.,"Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561703/),nM,38.5,145586,DB00722,Lisinopril
,24561703,Cmax,The Cmax obtained following oral administration of the drug was 0.082 μM and LisW-S had an apparent terminal elimination half-life of around 3.1 h.,"Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561703/),μM,0.082,145587,DB00722,Lisinopril
,24561703,apparent terminal elimination half-life,The Cmax obtained following oral administration of the drug was 0.082 μM and LisW-S had an apparent terminal elimination half-life of around 3.1 h.,"Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561703/),h,3.1,145588,DB00722,Lisinopril
,24561703,oral bioavailability,The pharmacokinetic data indicate that the oral bioavailability of LisW-S was approximately 5.4%.,"Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24561703/),%,5.4,145589,DB00722,Lisinopril
,9640348,clearance,"2. In this study, 10 patients with mild renal impairment (51Cr-EDTA clearance 63.7 +/- 8.3 ml.min-1.1.73 m-2) and heavy proteinuria (8.2 +/- 2.3 g/ 24 h) were given lisinopril (10-20 mg) for 6 weeks.","Proximal renal tubular peptide catabolism, ammonia excretion and tubular injury in patients with proteinuria: before and after lisinopril. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640348/),[ml] / [(m)^2·min],63.7,153340,DB00722,Lisinopril
,9640348,fractional degradation,"This was associated with a reduction in metabolism over 26 h (from 1.7 +/- 0.1 to 1.2 +/- 0.1% dose/h, P < 0.01) and in fractional degradation of aprotinin (from 0.08 +/- 0.02 to 0.04 +/- 0.007/h, P < 0.04).","Proximal renal tubular peptide catabolism, ammonia excretion and tubular injury in patients with proteinuria: before and after lisinopril. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640348/),1/[h],0.08,153341,DB00722,Lisinopril
,9640348,fractional degradation,"This was associated with a reduction in metabolism over 26 h (from 1.7 +/- 0.1 to 1.2 +/- 0.1% dose/h, P < 0.01) and in fractional degradation of aprotinin (from 0.08 +/- 0.02 to 0.04 +/- 0.007/h, P < 0.04).","Proximal renal tubular peptide catabolism, ammonia excretion and tubular injury in patients with proteinuria: before and after lisinopril. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640348/),1/[h],0.04,153342,DB00722,Lisinopril
,9640348,Ammonia,"Ammonia excretion also fell significantly (from 1.2 +/- 0.1 to 0.6 +/- 0.1 mmol/h, P < 0.0001), as did both total urinary N-acetyl-beta-D-glucosaminidase (P < 0.0001) and the N-acetyl-beta-D-glucosaminidase 'A2' isoenzyme (P < 0.015).","Proximal renal tubular peptide catabolism, ammonia excretion and tubular injury in patients with proteinuria: before and after lisinopril. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640348/),[mM] / [h],1.2,153343,DB00722,Lisinopril
,9640348,excretion,"Ammonia excretion also fell significantly (from 1.2 +/- 0.1 to 0.6 +/- 0.1 mmol/h, P < 0.0001), as did both total urinary N-acetyl-beta-D-glucosaminidase (P < 0.0001) and the N-acetyl-beta-D-glucosaminidase 'A2' isoenzyme (P < 0.015).","Proximal renal tubular peptide catabolism, ammonia excretion and tubular injury in patients with proteinuria: before and after lisinopril. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640348/),[mM] / [h],1.2,153344,DB00722,Lisinopril
,9640348,excretion,"Ammonia excretion also fell significantly (from 1.2 +/- 0.1 to 0.6 +/- 0.1 mmol/h, P < 0.0001), as did both total urinary N-acetyl-beta-D-glucosaminidase (P < 0.0001) and the N-acetyl-beta-D-glucosaminidase 'A2' isoenzyme (P < 0.015).","Proximal renal tubular peptide catabolism, ammonia excretion and tubular injury in patients with proteinuria: before and after lisinopril. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9640348/),[mM] / [h],0.6,153345,DB00722,Lisinopril
,17221934,limit of detection,"The limit of detection and lower limit of quantification in human plasma were 1 and 2 ng/mL, respectively.",Rapid quantification of lisinopril in human plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221934/),[ng] / [ml],1,155905,DB00722,Lisinopril
,17221934,limit of detection,"The limit of detection and lower limit of quantification in human plasma were 1 and 2 ng/mL, respectively.",Rapid quantification of lisinopril in human plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221934/),[ng] / [ml],2,155906,DB00722,Lisinopril
,30460043,half-life,The average half-life of lisinopril is 12.6 h and the above-mentioned dose able to sustain its IC50 value till the 36 h.,Ocular kinetics and safety of intravitreally injected angiotensin converting enzyme inhibitor lisinopril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30460043/),h,12.6,158503,DB00722,Lisinopril
,2442558,urinary recovery,Mean urinary recovery of lisinopril was found to be 15% following oral administration and 88% following intravenous administration.,"Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2442558/),%,15,170982,DB00722,Lisinopril
,2442558,urinary recovery,Mean urinary recovery of lisinopril was found to be 15% following oral administration and 88% following intravenous administration.,"Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2442558/),%,88,170983,DB00722,Lisinopril
,22345389,flow rate,The flow rate was 1.2 mL/min.,A sensitive and rapid determination of ranitidine in human plasma by HPLC with fluorescence detection and its application for a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22345389/),[ml] / [min],1.2,178311,DB00722,Lisinopril
,22345389,recovery,The mean recovery was determined to be 96.40 ± 0.02%.,A sensitive and rapid determination of ranitidine in human plasma by HPLC with fluorescence detection and its application for a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22345389/),%,96.40,178312,DB00722,Lisinopril
,18368945,maximum concentration (Cmax),"The mean maximum concentration (Cmax) of the test and reference were found to be 60.41 +/- 20.07 ng/mL and 61.11 +/- 19.36 ng/mL, respectively.",Bioequivalence evaluation of two brands of lisinopril tablets by in vitro comparative dissolution test and in vivo bioequivalence test. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18368945/),[ng] / [ml],60.41,179894,DB00722,Lisinopril
,18368945,maximum concentration (Cmax),"The mean maximum concentration (Cmax) of the test and reference were found to be 60.41 +/- 20.07 ng/mL and 61.11 +/- 19.36 ng/mL, respectively.",Bioequivalence evaluation of two brands of lisinopril tablets by in vitro comparative dissolution test and in vivo bioequivalence test. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18368945/),[ng] / [ml],61.11,179895,DB00722,Lisinopril
,18368945,AUC(0-t),"As for the AUC(0-t) and the AUC(0-infinity), test values were 792.73 +/- 273.41 ng x mL(-1) x h, 862.74 +/- 303.81 ng x mL(-1) x h and the reference values were 841.66 +/- 286.07 ng . mL(-1) x h, 906.97 +/- 318.72 ng x mL(-1) x h, respectively.",Bioequivalence evaluation of two brands of lisinopril tablets by in vitro comparative dissolution test and in vivo bioequivalence test. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18368945/),[h·ng] / [ml],792.73,179896,DB00722,Lisinopril
,18368945,AUC(0-t),"As for the AUC(0-t) and the AUC(0-infinity), test values were 792.73 +/- 273.41 ng x mL(-1) x h, 862.74 +/- 303.81 ng x mL(-1) x h and the reference values were 841.66 +/- 286.07 ng . mL(-1) x h, 906.97 +/- 318.72 ng x mL(-1) x h, respectively.",Bioequivalence evaluation of two brands of lisinopril tablets by in vitro comparative dissolution test and in vivo bioequivalence test. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18368945/),[h·ng] / [ml],841.66,179897,DB00722,Lisinopril
,18368945,AUC(0-infinity),"As for the AUC(0-t) and the AUC(0-infinity), test values were 792.73 +/- 273.41 ng x mL(-1) x h, 862.74 +/- 303.81 ng x mL(-1) x h and the reference values were 841.66 +/- 286.07 ng . mL(-1) x h, 906.97 +/- 318.72 ng x mL(-1) x h, respectively.",Bioequivalence evaluation of two brands of lisinopril tablets by in vitro comparative dissolution test and in vivo bioequivalence test. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18368945/),[h·ng] / [ml],862.74,179898,DB00722,Lisinopril
,18368945,AUC(0-infinity),"As for the AUC(0-t) and the AUC(0-infinity), test values were 792.73 +/- 273.41 ng x mL(-1) x h, 862.74 +/- 303.81 ng x mL(-1) x h and the reference values were 841.66 +/- 286.07 ng . mL(-1) x h, 906.97 +/- 318.72 ng x mL(-1) x h, respectively.",Bioequivalence evaluation of two brands of lisinopril tablets by in vitro comparative dissolution test and in vivo bioequivalence test. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18368945/),[h·ng] / [ml],906.97,179899,DB00722,Lisinopril
,18307734,bioavailability,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),%,2.6 and 5.0,185713,DB00722,Lisinopril
,18307734,IC50,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),[nM] / [l],0.6,185714,DB00722,Lisinopril
,18307734,plasma half-life,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),h,23-36,185715,DB00722,Lisinopril
,15282107,recovery,"The mean recovery of lisinopril from plasma and urine was 63.41 and 74.08%, respectively.",An HPLC method for the determination of lisinopril in human plasma and urine with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282107/),%,63.41,193663,DB00722,Lisinopril
,15282107,recovery,"The mean recovery of lisinopril from plasma and urine was 63.41 and 74.08%, respectively.",An HPLC method for the determination of lisinopril in human plasma and urine with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282107/),%,74.08,193664,DB00722,Lisinopril
,2547465,half-life for the terminal phase,The half-life for the terminal phase (approximately 40 h) was not predictive of steady-state parameters when ten daily doses (q24h) of lisinopril were administered orally to healthy volunteers.,Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547465/),h,40,197547,DB00722,Lisinopril
,2547465,effective half-life for accumulation,The mean effective half-life for accumulation was 12.6 h.,Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547465/),h,12.6,197548,DB00722,Lisinopril
,2547465,accumulation ratio,The mean accumulation ratio was 1.38.,Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547465/),,1.38,197549,DB00722,Lisinopril
,19007490,extraction efficiencies,The extraction efficiencies were approximately 80% and recoveries of method were in range of 94.4-98.2%.,Development and validation of LC-MS method for the determination of lisinopril in human plasma and its application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19007490/),%,80,219659,DB00722,Lisinopril
,19007490,recoveries,The extraction efficiencies were approximately 80% and recoveries of method were in range of 94.4-98.2%.,Development and validation of LC-MS method for the determination of lisinopril in human plasma and its application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19007490/),%,94.4-98.2,219660,DB00722,Lisinopril
,2900730,CLR/fu.,"The CLR/fu.GFR, where fu is the unbound fraction, became 1.10 +/- 0.09 and 1.25 +/- 0.25, respectively.",Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900730/),,1.10,221673,DB00722,Lisinopril
,2900730,CLR/fu.,"The CLR/fu.GFR, where fu is the unbound fraction, became 1.10 +/- 0.09 and 1.25 +/- 0.25, respectively.",Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900730/),,1.25,221674,DB00722,Lisinopril
,2203579,Absorption,"Absorption of the active diacids is generally poor, and moderate (typically 30 to 70%) for the prodrugs.",Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),%,30 to 70,223514,DB00722,Lisinopril
,2203579,bioavailability,The bioavailability of lisinopril is about 25%.,Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),%,25,223515,DB00722,Lisinopril
,2203579,Half-lives of accumulation,Half-lives of accumulation are of the order of 12 hours; protein binding varies from little (lisinopril) to 90% (benazeprilat).,Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),h,12,223516,DB00722,Lisinopril
,2203579,protein binding,Half-lives of accumulation are of the order of 12 hours; protein binding varies from little (lisinopril) to 90% (benazeprilat).,Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),%,90,223517,DB00722,Lisinopril
,2559191,J*max,"The estimated dimensionless carrier parameters for 2 are J*max = 0.16, Km = 0.08 mM, P*c = 2.0, and P*m = 0.25; for lisinopril, passive absorption is not significant and its absorption is nonpassive: J*max = 0.032, Km = 0.082 mM, and P*c = 0.39 (where J*max is the maximal flux, Km is the Michaelis constant, P*c is the carrier permeability, and P*m is the passive permeability).","Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2559191/),,0.16,227785,DB00722,Lisinopril
,2559191,Km,"The estimated dimensionless carrier parameters for 2 are J*max = 0.16, Km = 0.08 mM, P*c = 2.0, and P*m = 0.25; for lisinopril, passive absorption is not significant and its absorption is nonpassive: J*max = 0.032, Km = 0.082 mM, and P*c = 0.39 (where J*max is the maximal flux, Km is the Michaelis constant, P*c is the carrier permeability, and P*m is the passive permeability).","Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2559191/),mM,0.08,227786,DB00722,Lisinopril
,2559191,P*c,"The estimated dimensionless carrier parameters for 2 are J*max = 0.16, Km = 0.08 mM, P*c = 2.0, and P*m = 0.25; for lisinopril, passive absorption is not significant and its absorption is nonpassive: J*max = 0.032, Km = 0.082 mM, and P*c = 0.39 (where J*max is the maximal flux, Km is the Michaelis constant, P*c is the carrier permeability, and P*m is the passive permeability).","Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2559191/),,2,227787,DB00722,Lisinopril
,2559191,J*max,"The estimated dimensionless carrier parameters for 2 are J*max = 0.16, Km = 0.08 mM, P*c = 2.0, and P*m = 0.25; for lisinopril, passive absorption is not significant and its absorption is nonpassive: J*max = 0.032, Km = 0.082 mM, and P*c = 0.39 (where J*max is the maximal flux, Km is the Michaelis constant, P*c is the carrier permeability, and P*m is the passive permeability).","Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2559191/),,0.032,227788,DB00722,Lisinopril
,2559191,Km,"The estimated dimensionless carrier parameters for 2 are J*max = 0.16, Km = 0.08 mM, P*c = 2.0, and P*m = 0.25; for lisinopril, passive absorption is not significant and its absorption is nonpassive: J*max = 0.032, Km = 0.082 mM, and P*c = 0.39 (where J*max is the maximal flux, Km is the Michaelis constant, P*c is the carrier permeability, and P*m is the passive permeability).","Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2559191/),mM,0.082,227789,DB00722,Lisinopril
,2540786,urinary recovery,"3. Mean urinary recovery of lisinopril was 15 and 88% following oral and intravenous administration, respectively; absorption/bioavailability of lisinopril based on urinary recovery ratios was 16%, less than that found in normal subjects.",The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2540786/),%,15,227959,DB00722,Lisinopril
,2540786,urinary recovery,"3. Mean urinary recovery of lisinopril was 15 and 88% following oral and intravenous administration, respectively; absorption/bioavailability of lisinopril based on urinary recovery ratios was 16%, less than that found in normal subjects.",The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2540786/),%,88,227960,DB00722,Lisinopril
,2540786,absorption/bioavailability,"3. Mean urinary recovery of lisinopril was 15 and 88% following oral and intravenous administration, respectively; absorption/bioavailability of lisinopril based on urinary recovery ratios was 16%, less than that found in normal subjects.",The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2540786/),%,16,227961,DB00722,Lisinopril
,1665181,peak serum levels,"When given alone, peak serum levels of lisinopril (attained 6-8 hours post dose) were 44 ng/ml.",The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1665181/),[ng] / [ml],44,238465,DB00722,Lisinopril
,1665181,Urinary recovery,Urinary recovery was 17.6% of the dose.,The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1665181/),,17,238466,DB00722,Lisinopril
,1665181,peak serum concentration,"Dosing with hydrochlorothiazide alone resulted in a mean peak serum concentration of 53 ng/ml, 2-6 hours post dose.",The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1665181/),[ng] / [ml],53,238467,DB00722,Lisinopril
,19433973,first-order elimination half-life,"Metformin concentrations decreased to 97 microg/mL 28 hours after the ingestion on CVVH, with a first-order elimination half-life of 11.3 hours (r(2) = 0.99) and a clearance of 56.2 mL/min.",The MALAdy of metformin poisoning: Is CVVH the cure? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19433973/),h,11.3,239277,DB00722,Lisinopril
,19433973,clearance,"Metformin concentrations decreased to 97 microg/mL 28 hours after the ingestion on CVVH, with a first-order elimination half-life of 11.3 hours (r(2) = 0.99) and a clearance of 56.2 mL/min.",The MALAdy of metformin poisoning: Is CVVH the cure? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19433973/),[ml] / [min],56.2,239278,DB00722,Lisinopril
,2853897,urinary elimination,"3. After lisinopril alone, urinary elimination of unchanged lisinopril was 13% dose in 72 h, and after combined therapy was 17% dose.",A study of the potential pharmacokinetic interaction of lisinopril and digoxin in normal volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2853897/),%,13,241403,DB00722,Lisinopril
,2853897,urinary elimination,"3. After lisinopril alone, urinary elimination of unchanged lisinopril was 13% dose in 72 h, and after combined therapy was 17% dose.",A study of the potential pharmacokinetic interaction of lisinopril and digoxin in normal volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2853897/),%,17,241404,DB00722,Lisinopril
,33048477,time to reach maximum lisinopril concentration,"In contrast, there were no significant differences in time to reach maximum lisinopril concentration (6 hours in both phases) and renal clearance of lisinopril (57.7 mL/minute in control vs. 56.9 mL/minute in GTE).",Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33048477/),h,6,255488,DB00722,Lisinopril
,33048477,renal clearance,"In contrast, there were no significant differences in time to reach maximum lisinopril concentration (6 hours in both phases) and renal clearance of lisinopril (57.7 mL/minute in control vs. 56.9 mL/minute in GTE).",Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33048477/),[ml] / [min],57.7,255489,DB00722,Lisinopril
,33048477,renal clearance,"In contrast, there were no significant differences in time to reach maximum lisinopril concentration (6 hours in both phases) and renal clearance of lisinopril (57.7 mL/minute in control vs. 56.9 mL/minute in GTE).",Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33048477/),[ml] / [min],56.9,255490,DB00722,Lisinopril
,22845880,ESA index,The mean ESA index of all patients was 27·90±25·84 (IU/week/kg)/(g/dL).,Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845880/),[iu·kg·week] / [dl·g],27·90,266288,DB00722,Lisinopril
,22845880,AUC1,"Average lisinopril AUC1 was 1212·48±1209·75 [mg*h/L], whereas AUC2 averaged 947·67±977·07 [mg*h/L].",Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845880/),[h·mg] / [l],1212·48,266289,DB00722,Lisinopril
,22845880,AUC2,"Average lisinopril AUC1 was 1212·48±1209·75 [mg*h/L], whereas AUC2 averaged 947·67±977·07 [mg*h/L].",Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845880/),[h·mg] / [l],947·67,266290,DB00722,Lisinopril
